Revenue was 17.3% higher at $8.2 million from $7.0 million last year, on the back of higher contribution from its Obstetrics & Gynaecology (O&G), Cancer-related, and Dermatology segments, as well as maiden contribution from its new Paediatrics segment.
SINGAPORE (May 15): Phillip Capital is maintaining its “accumulate” recommendation on Singapore O&G (SOG) with a target price of 42 cents.
The group on Monday announced that its 1Q18 earnings have increased by 23.7% to $2.5 million, compared to $2.0 million in 1Q17.
